David A. Johnson is founder and principal of Endurance Capital Management, a New Jersey Limited Liability Company. As an investor entrepreneur, David invests in stocks, bonds, options, ETFs, REITs, real estate, closed end funds and alternative investment funds such as hedge funds and private credit. With over 30 years’ experience in investing, David holds a Master of Science (MS) Degree in Finance, with a concentration in Investment Analysis, from Boston University, a Certificate in Financial Planning, and ...

TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN GG00B1ZBD492 Issuer Name NB PRIVATE EQUITY PARTNERS LIMITED UK or Non-UK Issuer Non-UK 2. Reason for Notification An acquisition or disposal of voting rights; An event changing the breakdown of voting rights 3. Details of person subject to the notification obligation Name Quilter Plc City of registered office (if applicable) London Country of registered office (if applicable) United Kingdom 4. Details of the shareholder Full name ...

Innospec Inc. (IOSP) recorded a profit of $32.8 million or $1.31 per share in first-quarter 2025, down from a profit of $41.4 million or $1.65 per share in the year-ago quarter.Barring one-time items, earnings came in at $1.42 per share, down from $1.75 per share a year ago. It topped the Zacks Consensus Estimate of $1.40.The company’s revenues fell roughly 12% year over year to $440.8 million in the quarter. It missed the Zacks Consensus Estimate of $459.3 million. IOSP saw strong results in the Fuel Speci ...

Core Viewpoint - Autonomix Medical, Inc. is participating in the Virtual Investor Closing Bell Series to showcase its innovative medical device technology focused on precision nerve-targeted treatments [2][3]. Company Overview - Autonomix Medical, Inc. is a medical device company dedicated to advancing technologies for diagnosing and treating diseases related to the nervous system [5]. - The company's first-in-class platform system technology features a catheter-based microchip sensing array designed to detect and differentiate neural signals with greater sensitivity than existing technologies [5][6]. Technology and Applications - The initial development of the technology is aimed at treating pain, specifically targeting pancreatic cancer, which is known for causing severe pain and lacks reliable treatment options [6]. - The technology has the potential to address a wide range of indications, including cardiology, hypertension, and chronic pain management, across various diseases [6]. Event Details - The event will feature a corporate overview by Brad Hauser, President and CEO, and will include a live Q&A session for investors and interested parties [3][4]. - The live video webcast will be accessible on the company's website, with a replay available for 90 days following the event [4].

Core Points - Volatus Aerospace Inc. has completed a shares-for-debt transaction, issuing 20,174,280 common shares and 17,640,000 warrants to settle a debt of $3,026,142 [1][2] - The common shares were issued at a deemed price of $0.15 per share, while each warrant is exercisable at $0.20 per share for three years, with potential acceleration based on trading price conditions [2][3] - The transaction is subject to a hold period of four months and one day and requires final approval from the TSX Venture Exchange (TSXV) [3][4] Company Overview - Volatus Aerospace is a leader in global aerial solutions, focusing on intelligence and cargo services, with over 100 years of combined institutional knowledge in aviation [5] - The company serves various industries, including oil and gas, utilities, healthcare, and public safety, aiming to enhance operational efficiency, safety, and sustainability [5]

Bitfarms Ltd. (BITF) came out with a quarterly loss of $0.04 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.02 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this company would post a loss of $0.04 per share when it actually produced earnings of $0.03, delivering a surprise of 175%.Over the last four quarters, the company has surpassed consensus EPS estimates three times.Bitfarms, which belongs to the Zacks Techn ...

Chicago Atlantic BDC, Inc. (LIEN) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of $0.34. This compares to loss of $0.01 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -200%. A quarter ago, it was expected that this company would post earnings of $0.29 per share when it actually produced earnings of $0.35, delivering a surprise of 20.69%.Over the last four quarters, the company has surp ...

ARS Pharmaceuticals, Inc. (SPRY) came out with a quarterly loss of $0.35 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.11 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this company would post a loss of $0.04 per share when it actually produced earnings of $0.52, delivering a surprise of 1,400%.Over the last four quarters, the company has surpassed consensus EPS estimates just once.ARS Pharmaceuticals, Inc., whi ...

Verve Therapeutics (VERV) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.71. This compares to loss of $0.59 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 50.70%. A quarter ago, it was expected that this biotechnology firm would post a loss of $0.72 per share when it actually produced a loss of $0.58, delivering a surprise of 19.44%.Over the last four quarters, the compan ...

Cellebrite DI Ltd. (CLBT) came out with quarterly earnings of $0.10 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.08 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 11.11%. A quarter ago, it was expected that this company would post earnings of $0.10 per share when it actually produced earnings of $0.10, delivering no surprise.Over the last four quarters, the company has su ...